Mesoblast

MESO12 Feb 2025
Healthcare
$18.4
+0.02 (+1.86%)
Lowest Today
$18.38
Highest Today
$18.68
Today’s Open
$18.4
Prev. Close
$18.24
52 Week High
$22
52 Week Low
$1.83
To Invest in Mesoblast

Mesoblast

Healthcare
MESO12 Feb 2025
+0.02 (+1.86%)
1M
3M
6M
1Y
5Y
Low
$18.38
Day’s Range
High
$18.68
18.38
52 Week Low
$1.83
52-Week Range
52 Week High
$22
1.83
1 Day
-
1 Week
-2.92%
1 month return
+7.54%
3 month return
+84.15%
6 month return
+190.6%
1 Year return
+875.93%
3 Years return
+134.57%
5 Years return
-5.24%
10 Years return
-
Institutional Holdings
iShares Biotechnology ETF
0.49
Group One Trading, LP
0.2
Morgan Stanley - Brokerage Accounts
0.14
Summit X, LLC
0.11
Susquehanna International Group, LLP
0.09
Prosperity Wealth Management Inc
0.07
Penbrook Management LLC
0.07

Market Status

Fundamentals
Market Cap
1137.62 mln
PB Ratio
4.96
PE Ratio
0
Enterprise Value
2466.96 mln
Total Assets
669.15 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Organisation
Mesoblast
Employees
73
Industry
Biotechnology
CEO
Dr. Silviu  Itescu FACP, FACRA, FRACP, MBBS (Hons)
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step